Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H3B-6545 in Japanese women with ER-positive, HER2-negative breast cancer
NCT04568902Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2020
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of H3B-6545 in breast cancer (4 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Dose-limiting Toxicities, Treatment Emergent Adverse Events at 36 months and 7 more. Started Sep 2020; status: completed.
02
Drugs
H3B-6545
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04568902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04568902.